Activation of JNK signaling has been confirmed to render chemotherapy resistance in a variety of malignancies, including hepatocellular carcinoma [40], gastric cancer [41], and pancreatic cancer [42]. Here, MAPK8 is linked to hepatocellular carcinoma.